Bubble Power: HistoSonics Raises $102M To Drive Non-Invasive Histotripsy Growth

Following FDA clearance of its Edison Histotripsy System in October 2023 for the non-invasive destruction of liver tumors using focused ultrasound, HistoSonics announces plans for $102m in new funding led by Alpha Wave Ventures. “Bubbles have never been so powerful,” the company says.

• Source: HistoSonics

HistoSonics will use $102m in Series D funding to scale its operations and accelerate commercial growth in the US and internationally as it joins with leading institutions to develop multi-disciplinary histotripsy liver programs.

The Minneapolis, MN-based company received US Food and Drug Administration de novo clearance in October 2023 for its Edison Histotripsy...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

More from Financing

More from Business